Boldine Ameliorates Estrogen Deficiency-Induced Bone Loss via Inhibiting Bone Resorption

about

Boldine Ameliorates Estrogen Deficiency-Induced Bone Loss via Inhibiting Bone Resorption

Item

http://www.wikidata.org/entity/Q57111009

description

im Januar 2018 veröffentlichter wissenschaftlicher Artikel

@de

wetenschappelijk artikel

@nl

наукова стаття, опублікована у 2018

@uk

name

Boldine Ameliorates Estrogen Deficiency-Induced Bone Loss via Inhibiting Bone Resorption

@en

Boldine Ameliorates Estrogen Deficiency-Induced Bone Loss via Inhibiting Bone Resorption

@nl

type

Item

label

Boldine Ameliorates Estrogen Deficiency-Induced Bone Loss via Inhibiting Bone Resorption

@en

Boldine Ameliorates Estrogen Deficiency-Induced Bone Loss via Inhibiting Bone Resorption

@nl

prefLabel

Boldine Ameliorates Estrogen Deficiency-Induced Bone Loss via Inhibiting Bone Resorption

@en

Boldine Ameliorates Estrogen Deficiency-Induced Bone Loss via Inhibiting Bone Resorption

@nl

P1476

Boldine Ameliorates Estrogen Deficiency-Induced Bone Loss via Inhibiting Bone Resorption

@en

P2093

An-Min Chen

http://www.w3.org/2001/XMLSchema#string

Chen-He Zhou

http://www.w3.org/2001/XMLSchema#string

Hui Liao

http://www.w3.org/2001/XMLSchema#string

Hui Lin

http://www.w3.org/2001/XMLSchema#string

Hui Liu

http://www.w3.org/2001/XMLSchema#string

Kun Chen

http://www.w3.org/2001/XMLSchema#string

Peng Cheng

http://www.w3.org/2001/XMLSchema#string

Qing Yang

http://www.w3.org/2001/XMLSchema#string

Shuang Liang

http://www.w3.org/2001/XMLSchema#string

Virginia-Jeni Akila Parkman

http://www.w3.org/2001/XMLSchema#string

P2860

Screening, diagnosis and treatment of osteoporosis: a brief review

Serum CTX: a new marker of bone resorption that shows treatment effect more often than other markers because of low coefficient of variability and large changes with bisphosphonate therapy

Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis

Palmatine attenuates osteoclast differentiation and function through inhibition of receptor activator of nuclear factor-κb ligand expression in osteoblast cells.

Osteoporosis prevention, diagnosis, and therapy.

Selective estrogen-receptor modulators -- mechanisms of action and application to clinical practice.

Bisphosphonates for osteoporosis--where do we go from here?

The clinical epidemiology of male osteoporosis: a review of the recent literature.

Effect of Abaloparatide vs Placebo on New Vertebral Fractures in Postmenopausal Women With Osteoporosis: A Randomized Clinical Trial.

Inhibition of osteoclast differentiation and bone resorption by N-methylpyrrolidone

P304

1046

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3389/FPHAR.2018.01046

http://www.w3.org/2001/XMLSchema#string

P407

English

P478

http://www.w3.org/2001/XMLSchema#string

P577

2018-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

30271347

http://www.w3.org/2001/XMLSchema#string

P921

Farmakologi

P932

6146032

http://www.w3.org/2001/XMLSchema#string